NCT02813824View on ClinicalTrials.gov

Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

852

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

June 15, 2026

Study Completion Date

December 15, 2027

Conditions
Lynch Syndrome
Interventions
DRUG

Acetylsalicylic acid lysinate 300 mg

Daily dose during 4 years

DRUG

Placebo (for Aspirin 300)

Daily dose during 4 years

DRUG

Acetylsalicylic acid lysinate 100 mg

Daily dose during 4 years

DRUG

Placebo 100 (for Aspirin 100)

Daily dose during 4 years

Trial Locations (1)

93000

Hôpital Avicenne, Bobigny

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER